Research progress on immune checkpoint inhibitors in neoadjuvant therapy for gastric cancer

• 作者: Wenting Li Shiying Yu
• 来源期刊: 肿瘤学与转化医学（英文版）
• 年，卷（期）: 2022,（2）
• 页码范围: 74-82
• 页数: 9页
• 语种: 英文
• DOI: 10.1007/s10330-022-0551-1

摘要

In recent years, immune checkpoint inhibitors (ICIs) have become an important treatment strategy for advanced gastric cancer. Immunotherapy has gradually transitioned from a later-line to a first-line treatment for advanced gastric cancer. Simultaneously, more and more researchers have begun to pay attention to whether immunotherapy can be used for resectable gastric cancer. The current use of ICIs in the neoadjuvant treatment of gastric cancer is still in its exploratory stage, with a number of clinical trials currently underway. However, the available data show good application prospects. This article reviewsthe research progress on ICIs in the neoadjuvant therapy for gastric cancer and evokes some unresolved problems.